{"disease":{"id":"human-immunodeficiency-virus-type-1-hiv-1","name":"human immunodeficiency virus type 1 hiv 1"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07266831","title":"A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":570,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07370649","title":"Long-Acting Cabotegravir and Rilpivirine in People Living With HIV-1 Subtype A6: A Real-World Retrospective Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Pomeranian Medical University Szczecin","has_results":false},{"nct_id":"NCT06891066","title":"A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT05896761","title":"A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05896748","title":"Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"ViiV Healthcare","has_results":true},{"nct_id":"NCT05458102","title":"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"Gilead Sciences","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}